European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Polymeric cyclodextrin-based nanoparticles for combination therapy of castrate-resistant prostate cancer

Description du projet

L’administration de médicaments anticancéreux par les nanotechnologies

Les patients atteints d’un cancer de la prostate développent souvent une résistance aux médicaments contre la thérapie classique de privation d’androgènes, ce qui entraîne une rechute. Le projet POLAR STAR, financé par l’UE, travaillera sur une thérapie combinée ciblant et agissant en synergie simultanément contre plusieurs voies oncogènes. Les scientifiques utiliseront des nanovecteurs polymères biocompatibles, dont les composants sont déjà approuvés par les autorités réglementaires, pour administrer les derniers médicaments contre le cancer de la prostate avec une efficacité et une spécificité accrues, minimisant ainsi les effets non ciblés. POLAR STAR utilisera des techniques spectroscopiques avancées pour caractériser chimiquement et physiquement les nanovecteurs, et remplacera les expériences sur les animaux par des modèles de tissus prostatiques en 3D pour évaluer leurs performances.

Objectif

Prostate cancer (PC) is the fifth leading cause of cancer-related death worldwide. PC often presents in its Multidrug resistant form leaving the patient few survival chances. New approaches are required to overcome resistance-related problems in PC and nanomedicine holds a lot of premises to effectively contribute in this battle. In this frame POLAR STAR aims at the implementation of combination therapy to treat castrate-resistant PC. Our strategy is to exploit innovative nanotechnology to administer contemporarily different therapeutic agents that synergically exert their activity across multiple oncogenic pathways. We plan to use new mixed polymers based on biocompatible cyclodextrins as these building blocks are already FDA approved. Simple organic chemistry is pursued to implement target selectivity and in vivo tracking of the polymeric nanocarrier. The design is guided by the final goal, the future clinical application of nanocarriers to improve PC treatment, keeping in mind upgrade of the nanocarrier systems to large scale production. We will focus on the latest PC drugs suffering from side effects and emerging resistance as multiple cargo to be loaded. Full chemico-physical characterization of the systems is planned as well as assessment of the efficacy of loaded nanocarriers in cell cultures with different drug responsivity profiles. In order to reduce animal experiments POLAR STAR will take full advantage of 3D prostate tissue models for biological tests, an apporach at the forefront in drug design. We plan to reach our goal bringing together the expertise of the fellow and the supervisor supported by the private and academic teams hosting the fellow during secondments. POLAR STAR creates a multidisciplinary environment where all actors, public and private, will benefit from reciprocal transfer of knowledge. During the project the fellow will have the possibility to become a complete researcher improving also complementary skills.

Coordinateur

CONSIGLIO NAZIONALE DELLE RICERCHE
Contribution nette de l'UE
€ 171 473,28
Adresse
PIAZZALE ALDO MORO 7
00185 Roma
Italie

Voir sur la carte

Région
Centro (IT) Lazio Roma
Type d’activité
Research Organisations
Liens
Coût total
€ 171 473,28